{
  "id": 15885404,
  "title": "Genentech Presents New Pivotal Trial Data Across Broad Neuroimmunology Portfolio at MSToronto2026",
  "url": "https://urgent.news/2026/10/21/genentech-presents-new-pivotal-trial-data-across-broad",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-10-21T12:09:01.000Z",
  "source": {
    "name": "Financial Post",
    "slug": "financial-post",
    "url": "https://financialpost.com/pmn/business-wire-news-releases-pmn/genentech-presents-new-pivotal-trial-data-across-broad-neuroimmunology-portfolio-at-mstoronto2026"
  },
  "original_language": "en",
  "account": null,
  "summary": "Fenebrutinib FENtrepid and FENhance 1 & 2 late-breaking data demonstrate a therapeutic effect on chronic active lesions, addressing a primary driver of long-term disability progression in multiple sclerosis (MS) Fenebrutinib FENhance 1 & 2 Phase III pooled data show a 55% reduction in annualized relapse rate (ARR) vs active comparator Ocrevus OPERETTA 2 Phase III […]",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}